Institute for Cardiovascular Diseases of Vojvodina Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2019
NCT05366101
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Institute for Cardiovascular Diseases of Vojvodina

Active Ingredients

Drugs in Phase 3 Trials (2)

sacubitril (Entresto) (2 trials)

valsartan (diovan) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiomyopathies (Phase 3)

Cardiomyopathy, Hypertrophic (Phase 3)

Hypertrophy (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2